Some patients with prostate cancer have genetic mutations that may impact their treatment. A comprehensive, on-site genetic testing program, pioneered by urologists, could help to close the gap for this underutilized resource, reports a study in Urology Practice®, an Official Journal of the American Urological Association (AUA).
Some patients with prostate cancer have genetic mutations that may impact their treatment. A comprehensive, on-site genetic testing program, pioneered by urolog
Acceleration of the commercialization and R&D strategy to lay the groundwork for sales growth: Appointment of Gabriel Plan as Sales Director in France; Successful installation of
Ikonisys Reinforces Its Strategic Collaboration With Empire Genomics Following Excellent Results of Optimized Reagents in Detection of Bladder Cancer Cells finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
^ Original-Research: Ikonisys SA - von Sphene Capital GmbH Einstufung von Sphene Capital GmbH zu Ikonisys SA Unternehmen: Ikonisys SA ISIN: FR00140048X2 Anlass der Studie: Update Report Empfehlung: Buy seit: 23.06.2022 Kursziel: EUR 6,90 (unverändert) Kursziel auf Sicht von: 24 Monate Letzte Rat.